Dilesh Roadlines Pvt Ltd, acting on behalf of its promoters and promoter group, has submitted a disclosure of shareholding changes in Aarti Drugs Limited. The filing, dated June 25, 2026, details share acquisitions and disposals between May 29, 2024, and June 24, 2026. The net change in promoter group shareholding resulted in a decrease of 1.67%, bringing the total holding to 54.43% of the total paid-up share capital. This update adheres to SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Dilesh Roadlines Pvt Ltd Discloses Shareholding in Aarti Drugs Ltd.
Dilesh Roadlines Private Limited has formally communicated a significant disclosure regarding the shareholding of its promoters and the promoter group in Aarti Drugs Limited. This filing, made on June 25, 2026, provides a detailed account of the transactions undertaken between May 29, 2024, and June 24, 2026, covering both acquisitions and disposals of shares.
Key Shareholding Movements
The disclosure highlights that the promoter group’s total shareholding in Aarti Drugs Limited has seen a net reduction. Before these transactions, the promoter group held 55.70% of the total share capital. Following the reported acquisitions and sales, the holding has decreased by 1.67%, settling at 54.43% as of June 24, 2026. This movement reflects a net sale of -2,265,795 shares by the promoter group.
Detailed Transaction Breakdown
During the period under review, Dilesh Roadlines Private Limited itself experienced a reduction in its shareholding, disposing of 125,998 shares. Other entities within the promoter group also saw changes. Specifically, a total of 1,769,641 shares were sold via buyback or market sales by ‘Other Promoters (List attached)’. Conversely, ‘Market Purchase (List attached)’ saw an acquisition of 370,156 shares by ‘Other Promoters’. These combined activities resulted in the overall shift in the promoter group’s stake.
Total Share Capital and Voting Rights
The announcement also details the total equity share capital and voting capital. Before the acquisition/sale, the total equity share capital was 91,935,000. After the transactions, the total equity share capital stands at 91,270,000, reflecting a reduction of 665,000 shares due to a buyback of shares by the company in September 2024. The total diluted share capital after the said acquisition remains at 91,270,000.
Source: BSE
